15 results on '"Viale, P.L."'
Search Results
2. De Novo Malignancies After Kidney and Liver Transplantations: Experience on 582 Consecutive Cases
- Author
-
Baccarani, U., Adani, G.L., Montanaro, D., Risaliti, A., Lorenzin, D., Avellini, C., Tulissi, P., Groppuzzo, M., Currò, G., Luvisetto, F., Beltrami, A., Bresadola, V., Viale, P.L., and Bresadola, F.
- Published
- 2006
- Full Text
- View/download PDF
3. Comparison of Clinical and Pathological Staging and Long-Term Results of Liver Transplantation for Hepatocellular Carcinoma in a Single Transplant Center
- Author
-
Baccarani, U., Adani, G.L., Avellini, C., Lorenzin, D., Currò, G., Beltrami, A., Pasqualucci, A., Bresadola, V., Risaliti, A., Viale, P.L., Beltrami, C.A., and Bresadola, F.
- Published
- 2006
- Full Text
- View/download PDF
4. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
- Author
-
Gaibani, P., primary, Re, M.C., additional, Campoli, C., additional, Viale, P.L., additional, and Ambretti, S., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Management of KPC-producing Klebsiella pneumoniae infections
- Author
-
Bassetti, M. Giacobbe, D.R. Giamarellou, H. Viscoli, C. Daikos, G.L. Dimopoulos, G. De Rosa, F.G. Giamarellos-Bourboulis, E.J. Rossolini, G.M. Righi, E. Karaiskos, I. Tumbarello, M. Nicolau, D.P. Viale, P.L. Poulakou, G. Critically Ill Patients Study Group of the European Society of Clinical Microbiology Infectious Disease (ESCMID) Hellenic Society of Chemotherapy (HSC) Societa Italiana di Terapia Antinfettiva (SITA)
- Abstract
Background: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic areas. Aims: To provide practical suggestion for physicians dealing with the management of KPC-KP infections in critically ill patients, based on expert opinions. Sources: PubMed search for relevant publications related to the management of KPC-KP infections. Contents: A panel of experts developed a list of 12 questions to be addressed. In view of the current lack of high-level evidence, they were asked to provide answers on the bases of their knowledge and experience in the field. The panel identified several key aspects to be addressed when dealing with KPC-KP in critically ill patients (preventing colonization in the patient, preventing infection in the colonized patient and colonization of his or her contacts, reducing mortality in the infected patient by rapidly diagnosing the causative agent and promptly adopting the best therapeutic strategy) and provided related suggestions that were based on the available observational literature and the experience of panel members. Implications: Diagnostic technologies could speed up the diagnosis of KPC-KP infections. Combination treatment should be preferred to monotherapy in cases of severe infections. For non–critically ill patients without severe infections, results from randomized clinical trials are needed for ultimately weighing benefits and costs of using combinations rather than monotherapy. Multifaceted infection control interventions are needed to decrease the rates of colonization and cross-transmission of KPC-KP. © 2017 European Society of Clinical Microbiology and Infectious Diseases
- Published
- 2018
6. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae
- Author
-
Russo, A., primary, Falcone, M., additional, Gutiérrez-Gutiérrez, B., additional, Calbo, E., additional, Almirante, B., additional, Viale, P.L., additional, Oliver, A., additional, Ruiz-Garbajosa, P., additional, Gasch, O., additional, Gozalo, M., additional, Pitout, J., additional, Akova, M., additional, Peña, C., additional, Cisneros, J.M., additional, Hernández-Torres, A., additional, Farcomeni, A., additional, Prim, N., additional, Origüen, J., additional, Bou, G., additional, Tacconelli, E., additional, Tumbarello, M., additional, Hamprecht, A., additional, Karaiskos, I., additional, de la Calle, C., additional, Pérez, F., additional, Schwaber, M.J., additional, Bermejo, J., additional, Lowman, W., additional, Hsueh, P.-R., additional, Mora-Rillo, M., additional, Rodriguez-Gomez, J., additional, Souli, M., additional, Bonomo, R.A., additional, Paterson, D.L., additional, Carmeli, Y., additional, Pascual, A., additional, Rodríguez-Baño, J., additional, and Venditti, M., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Liver transplantation from old donors into HCV and non-HCV recipients
- Author
-
Baccarani, U, Adani, G.L, Toniutto, P, Sainz, M, Lorenzin, D, Viale, P.L, Ramacciato, G, Risaliti, A, and Bresadola, F
- Published
- 2004
- Full Text
- View/download PDF
8. TICK-BORNE ENCEPHALITIS (TBE): PRIMO CASO IN FRIULI VENEZIA GIULIA (FVG)
- Author
-
Ruscio, M., primary, Beltrame, A., additional, Cruciatti, B., additional, Scudeller, L., additional, Rorato, G., additional, Gigli, G.L., additional, and Viale, P.L., additional
- Published
- 2004
- Full Text
- View/download PDF
9. DIAGNOSI INUSUALE DI TRICOCEFALOSI CON L’ESAME UROPARASSITOLOGICO.
- Author
-
Arzese, A., primary, Beltrame, A., additional, De Cecco, L., additional, Bragantini, F., additional, Tavio, M., additional, and Viale, P.L., additional
- Published
- 2004
- Full Text
- View/download PDF
10. Intestinal co-infection byCyclosporasp. andCryptosporidium parvum: first report in an aids patient
- Author
-
Scaglia, M., primary, Gatti, S., additional, Bassi, P., additional, Viale, P.L., additional, Novati, S., additional, and Ranieri, S., additional
- Published
- 1994
- Full Text
- View/download PDF
11. Intestinal co-infection by Cyclosporasp. and Cryptosporidium parvum: first report in an aids patient
- Author
-
Scaglia, M., Gatti, S., Bassi, P., Viale, P.L., Novati, S., Ranieri, S., Scaglia, M., Gatti, S., Bassi, P., Viale, P.L., Novati, S., and Ranieri, S.
- Abstract
Cyclosporais a recently described new human pathogenic coccidian causing intermittent diarrhoeal enteritis which may persist for weeks or months in immunocompetent subjects, particularly travellers visiting some tropical areas and countries, such as Nepal, the Caribbean, Peru and Mexico. More rarely this enteric pathogen affects immunocompromised humans, namely HIV-infected people or AIDS patients, with same clinical pictures recognized in normal hosts. We describe the first case of Cyclosporasp. and Cryptosporidium parvumassociated diarrhoeal enteritis in an adult AIDS patient.
- Published
- 1994
- Full Text
- View/download PDF
12. Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- Author
-
Ivana Castaniere, Jovana Milic, Marianna Menozzi, Maddalena Giannella, Marianna Meschiari, Lucio Brugioni, Alessandro Cozzi-Lepri, Massimo Girardis, Cinzia Puzzolante, Enrico Clini, Margherita Di Gaetano, Vanni Borghi, Sara K. Tedeschi, Erica Franceschini, Michele Bartoletti, Gabriella Orlando, Luca Tabbì, Antonella Santoro, Andrea Bedini, Carlo Salvarani, Federica Carli, Federico Pea, Antonello Pietrangelo, Luca Corradi, Gianluca Cuomo, Roberto Tonelli, Pierluigi Viale, Riccardo Fantini, Andrea Cossarizza, Giovanni Guaraldi, Renato Pascale, Cristina Mussini, Marco Massari, Giovanni Dolci, Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., Franceschini E., Cuomo G., Orlando G., Borghi V., Santoro A., Di Gaetano M., Puzzolante C., Carli F., Bedini A., Corradi L., Fantini R., Castaniere I., Tabbi L., Girardis M., Tedeschi S., Giannella M., Bartoletti M., Pascale R., Dolci G., Brugioni L., Pietrangelo A., Cossarizza A., Pea F., Clini E., Salvarani C., Massari M., Viale P.L., and Mussini C.
- Subjects
Mechanical ventilation ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,Immunology ,Low molecular weight heparin ,Retrospective cohort study ,Azithromycin ,medicine.disease ,Article ,chemistry.chemical_compound ,Pneumonia ,Tocilizumab ,chemistry ,Rheumatology ,Internal medicine ,severe covid-19, tocilizumab ,medicine ,Clinical endpoint ,Immunology and Allergy ,business ,Letters to the Editor ,Cohort study ,medicine.drug - Abstract
Background: No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods: This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable. The primary endpoint was a composite of invasive mechanical ventilation or death. Treatment groups were compared using Kaplan-Meier curves and Cox regression analysis after adjusting for sex, age, recruiting centre, duration of symptoms, and baseline Sequential Organ Failure Assessment (SOFA) score. Findings: Of 1351 patients admitted, 544 (40%) had severe COVID-19 pneumonia and were included in the study. 57 (16%) of 365 patients in the standard care group needed mechanical ventilation, compared with 33 (18%) of 179 patients treated with tocilizumab (p=0·41; 16 [18%] of 88 patients treated intravenously and 17 [19%] of 91 patients treated subcutaneously). 73 (20%) patients in the standard care group died, compared with 13 (7%; p
- Published
- 2020
13. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
- Author
-
Simone Ambretti, Paolo Gaibani, Maria Carla Re, Pierluigi Viale, Caterina Campoli, Gaibani P., Re M.C., Campoli C., Viale P.L., and Ambretti S.
- Subjects
Microbiology (medical) ,Klebsiella pneumoniae ,Avibactam ,Population ,Ceftazidime ,Bacteremia ,Microbial Sensitivity Tests ,bla ,Meropenem/vaborbactam resistance ,Meropenem ,Microbiology ,Tertiary Care Centers ,chemistry.chemical_compound ,Ceftazidime/avibactam resistance ,Drug Resistance, Multiple, Bacterial ,copy number ,polycyclic compounds ,medicine ,Humans ,education ,Vaborbactam ,education.field_of_study ,Porin deficiency ,Whole Genome Sequencing ,biology ,Incidence ,Genomics ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,Antimicrobial ,Ceftazidime/avibactam ,Anti-Bacterial Agents ,Klebsiella Infections ,Drug Combinations ,KPC ,Carbapenem-Resistant Enterobacteriaceae ,Infectious Diseases ,Italy ,chemistry ,Mutation ,D179Y mutation ,Azabicyclo Compounds ,Genome, Bacterial ,medicine.drug - Abstract
Objectives The aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) strains isolated from patients with bloodstream infection. Methods We collected 120 carbapenemase producing Enterobacteriaceae (CPE) strains from unique patients hospitalized in two Italian hospitals between January 2018 to February 2019. Strains were phenotypically characterized for the type of carbapenemase production and susceptibility to ceftazidime/avibactam. Ceftazidime/avibactam-resistant strains were characterized by whole-genome sequencing. Results During the study period, we characterized 105 (87.5%) KPC producers among a total of 120 CPE strains. Ceftazidime/avibactam resistance was found in three KPC-Kp strains isolated from patients with no history of previous ceftazidime/avibactam-based treatment. Of note, two out of three ceftazidime–avibactam-resistant KPC-Kp were also resistant to meropenem/vaborbactam. Genomic characterization showed that a ceftazidime/avibactam-resistant KPC-Kp harboured a mixed population with D179Y mutated KPC-2, while the other two ceftazidime–avibactam-resistant KPC-Kp possessed non-functional ompK35-ompK37 and mutated ompK36 porins associated with higher copy number of blaKPC gene. Conclusions Our results showed that incidence of ceftazidime/avibactam resistance emerged in KCP-Kp strains independently from previous antimicrobial exposure. Resistance to ceftazidime/avibactam was associated with mutations within the blaKPC gene or porin deficiency associated with higher blaKPC copy number and is also related to the meropenem/vaborbactam resistance.
- Published
- 2020
14. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae
- Author
-
Robert A. Bonomo, Mónica Gozalo, Evelina Tacconelli, Axel Hamprecht, Julia Origüen, Benito Almirante, Increment investigators, Warren Lowman, Marco Falcone, Po-Ren Hsueh, Germán Bou, C. de la Calle, Belén Gutiérrez-Gutiérrez, Pierluigi Viale, Alessandro Russo, Yehuda Carmeli, Marta Mora-Rillo, Maria Souli, Mario Tumbarello, Reipi, Alessio Farcomeni, Mitchell J. Schwaber, José Miguel Cisneros, Esgbis, Alicia Hernandez-Torres, Murat Akova, Jesús Rodríguez-Baño, David L. Paterson, Federico Perez, Jorge Rodriguez-Gómez, Mario Venditti, Patricia Ruiz-Garbajosa, Esther Calbo, Antonio Oliver, Oriol Gasch, Johann D. D. Pitout, N. Prim, Ilias Karaiskos, Álvaro Pascual, Carmen Peña, Joaquín Bermejo, Russo, A., Falcone, M., Gutiérrez-Gutiérrez, B., Calbo, E., Almirante, B., Viale, P.L., Oliver, A., Ruiz-Garbajosa, P., Gasch, O., Gozalo, M., Pitout, J., Akova, M., Peña, C., Cisneros, J.M., Hernández-Torres, A., Farcomeni, A., Prim, N., Origüen, J., Bou, G., Tacconelli, E., Tumbarello, M., Hamprecht, A., Karaiskos, I., de la Calle, C., Pérez, F., Schwaber, M.J., Bermejo, J., Lowman, W., Hsueh, P.-R., Mora-Rillo, M., Rodriguez-Gomez, J., Souli, M., Bonomo, R.A., Paterson, D.L., Carmeli, Y., Pascual, A., Rodríguez-Baño, J., and Venditti, M.
- Subjects
0301 basic medicine ,Male ,Klebsiella pneumoniae ,ß-lactam/ß-lactamase inhibitor ,extended-spectrum ß-lactamases ,sepsis ,carbapenems ,septic shock ,ß-lactam/ß-lactamase inhibitors ,Aged ,Aged, 80 and over ,Anti-Bacterial Agents ,Drug Therapy, Combination ,Enterobacteriaceae ,Enterobacteriaceae Infections ,Female ,Humans ,Middle Aged ,Prognosis ,Retrospective Studies ,Sepsis ,Survival Analysis ,Treatment Outcome ,beta-Lactamase Inhibitors ,beta-Lactamases ,beta-Lactams ,Decision Support Techniques ,0302 clinical medicine ,Clinical endpoint ,80 and over ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,biology ,extended-spectrum ß-lactamase ,General Medicine ,Infectious Diseases ,Combination ,sepsi ,Settore SECS-S/01 - Statistica ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Infectious Disease ,carbapenem ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,In patient ,business.industry ,Proportional hazards model ,Septic shock ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Bacteremia ,business - Abstract
Purpose There are few data in the literature regarding sepsis or septic shock due to extended-spectrum β-lactamases (ESBL)-producing Enterobacteriaceae (E). The aim of this study was to assess predictors of outcome in septic patients with bloodstream infection (BSI) caused by ESBL-E. Methods Patients with severe sepsis or septic shock and BSI due to ESBL-E were selected from the INCREMENT database. The primary endpoint of the study was the evaluation of predictors of outcome after 30 days from development of severe sepsis or septic shock due to ESBL-E infection. Three cohorts were created for analysis: global, empirical-therapy and targeted-therapy cohorts. Results 367 septic patients were analysed. Overall mortality was 43.9% at 30 days. Escherichia coli (62.4%) and Klebsiella pneumoniae (27.2%) were the most frequent isolates. β-lactam/β-lactamase inhibitor (BLBLI) combinations were the most empirically used drug (43.6%), followed by carbapenems (29.4%). Empirical therapy was active in vitro in 249 (67.8%) patients, and escalation of antibiotic therapy was reported in 287 (78.2%) patients. Cox regression analysis showed that age, Charlson Comorbidity Index, McCabe classification, Pitt bacteremia score, abdominal source of infection and escalation of antibiotic therapy were independently associated with 30-day mortality. No differences in survival were reported in patients treated with BLBLI combinations or carbapenems in empirical or definitive therapy. Conclusions BSI due to ESBL-E in patients who developed severe sepsis or septic shock was associated with high 30-day mortality. Comorbidities, severity scores, source of infection and antibiotic therapy escalation were important determinants of unfavorable outcome.
- Published
- 2018
15. Management of KPC-producing Klebsiella pneumoniae infections
- Author
-
Mario Tumbarello, Daniele Roberto Giacobbe, Gian Maria Rossolini, Georgios Daikos, Ilias Karaiskos, F. G. De Rosa, P. Viale, Helen Giamarellou, Evangelos J. Giamarellos-Bourboulis, Matteo Bassetti, Claudio Viscoli, David P. Nicolau, Elda Righi, George Dimopoulos, G. Poulakou, Bassetti, M., Giacobbe, D.R., Giamarellou, H., Viscoli, C., Daikos, G.L., Dimopoulos, G., De Rosa, F.G., Giamarellos-Bourboulis, E.J., Rossolini, G.M., Righi, E., Karaiskos, I., Tumbarello, M., Nicolau, D.P., Viale, P.L., and Poulakou, G.
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Klebsiella pneumoniae ,030106 microbiology ,Psychological intervention ,beta-Lactam Resistance ,beta-Lactamases ,law.invention ,03 medical and health sciences ,Bacterial Proteins ,Randomized controlled trial ,law ,Humans ,Medicine ,Infection control ,Intensive care medicine ,Antibiotic treatment, ESCMID, Klebsiella pneumoniae, KPC, position paper, Microbiology (medical), Infectious Diseases ,Antibiotic treatment ,ESCMID ,KPC ,Position paper ,Infectious Diseases ,Therapeutic strategy ,biology ,business.industry ,Critically ill ,General Medicine ,biology.organism_classification ,Anti-Bacterial Agents ,Klebsiella Infections ,Observational study ,business ,position paper - Abstract
Antibiotic treatment; ESCMID; KPC; Klebsiella pneumoniae; position paper Background: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic areas. Aims: To provide practical suggestion for physicians dealing with the management of KPC-KP infections in critically ill patients, based on expert opinions. Sources: PubMed search for relevant publications related to the management of KPC-KP infections. Contents: A panel of experts developed a list of 12 questions to be addressed. In view of the current lack of high-level evidence, they were asked to provide answers on the bases of their knowledge and experience in the field. The panel identified several key aspects to be addressed when dealing with KPC-KP in critically ill patients (preventing colonization in the patient, preventing infection in the colonized patient and colonization of his or her contacts, reducing mortality in the infected patient by rapidly diagnosing the causative agent and promptly adopting the best therapeutic strategy) and provided related suggestions that were based on the available observational literature and the experience of panel members. Implications: Diagnostic technologies could speed up the diagnosis of KPC-KP infections. Combination treatment should be preferred to monotherapy in cases of severe infections. For nonâcritically ill patients without severe infections, results from randomized clinical trials are needed for ultimately weighing benefits and costs of using combinations rather than monotherapy. Multifaceted infection control interventions are needed to decrease the rates of colonization and cross-transmission of KPC-KP.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.